In an interview with the Korean Economic Daily Dong-Hoon Jin, CEO of Wellmarker Bio(WMBIO) stated that its targeted anti-cancer drug WM-S1-030 has recently received an approval from the Australian Therapeutic Goods Administration(TGA) for phase I clinical trial on February 23, 2021. If the phase 1a trial is well conducted, WMBIO plans to initiate phase 1b trial in the USA 2022 for patients who are resistant to chemotherapy.
During the interview, he also introduced the development status of the remaining eight pipelines. One of the lead pipeline WM-A1 is a novel immunotherapeutic antibody that is expected to enter phase 1 clinical trail at Australia in the second half of next year, 2022. It is being developed for cancer patients who have low response to MSD’s immunotherapy 'Keytruda’. In case of non-small-cell lung carcinoma (NSCLC) patients with no PD-L1 protein expression, the likelihood of having treatment effect is only 20%. In the meantime, WM-P1 an anti-cancer drug for liver cancer is planned to enter the preclinical stage at the end of next year.
Please click on the link below to read the full interview in Korean.
During the interview, he also introduced the development status of the remaining eight pipelines. One of the lead pipeline WM-A1 is a novel immunotherapeutic antibody that is expected to enter phase 1 clinical trail at Australia in the second half of next year, 2022. It is being developed for cancer patients who have low response to MSD’s immunotherapy 'Keytruda’. In case of non-small-cell lung carcinoma (NSCLC) patients with no PD-L1 protein expression, the likelihood of having treatment effect is only 20%. In the meantime, WM-P1 an anti-cancer drug for liver cancer is planned to enter the preclinical stage at the end of next year.
Please click on the link below to read the full interview in Korean.